HDL as a drug and nucleic acid delivery vehicle

Andras G. Lacko, Nirupama A. Sabnis, Bhavani Nagarajan, Walter J. McConathy

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.

Original languageEnglish
Pages (from-to)247
Number of pages1
JournalFrontiers in Pharmacology
Issue numberOCT
StatePublished - 2015


  • Drug delivery
  • HDL
  • Lipoproteins
  • Nucleic acid delivery
  • Therapeutics


Dive into the research topics of 'HDL as a drug and nucleic acid delivery vehicle'. Together they form a unique fingerprint.

Cite this